University of Texas MD Anderson Cancer Center


Hospital

Location:
Houston, United States (USA)


Publications in cooperation with FAU scientists


Go to first page Go to previous page 1 of 4 Go to next page Go to last page
Black, P.C., Goebell, P., Kamat, A.M., Nawroth, R., Seiler, R., Williams, S.B., & Schmitz-Dräger, B.J. (2019). Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. Urologic Oncology-Seminars and Original Investigations. https://dx.doi.org/10.1016/j.urolonc.2019.01.003
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Yang, Y., Wu, L., Shu, X., Lu, Y., Shu, X.-O., Cai, Q.,... Long, J. (2019). Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-18-2726
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403. https://dx.doi.org/10.1530/ERC-18-0332
Boormans, J.L., Zwarthoff, E.C., Black, P.C., Goebell, P., Kamat, A.M., Nawroth, R.,... Schmitz-Dräger, B.J. (2019). New horizons in bladder cancer research. Urologic Oncology-Seminars and Original Investigations. https://dx.doi.org/10.1016/j.urolonc.2018.12.014
Williams, S.B., Hudgins, H.K., Ray-Zack, M.D., Chamie, K., Smaldone, M.C., Boorjian, S.A.,... Gore, J.L. (2019). Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2(2), 119-125. https://dx.doi.org/10.1016/j.euo.2018.07.006
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Capper, D., Jones, D.T.W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D.,... Pfister, S.M. (2018). DNA methylation-based classification of central nervous system tumours. Nature, 555(7697), 469-474. https://dx.doi.org/10.1038/nature26000
Black, P.C., Goebell, P., Kamat, A.M., Nawroth, R., & Schmitz-Draeger, B.J. (2018). Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urologic Oncology-Seminars and Original Investigations, 36(9), 403-404. https://dx.doi.org/10.1016/j.urolonc.2017.11.006
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).
Brabletz, T., Kalluri, R., Nieto, M.A., & Weinberg, R.A. (2018). EMT in cancer. Nature Reviews Cancer, 18(2), 128-134. https://dx.doi.org/10.1038/nrc.2017.118
El Hallani, S., Udager, A.M., Bell, D., Fonseca, I., Thompson, L.D.R., Assaad, A.,... Chiosea, S. (2018). Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. American Journal of Surgical Pathology, 42(1), 18-27. https://dx.doi.org/10.1097/PAS.0000000000000933
Schäffner, I., Minakaki, G., Khan, M.A., Balta, E.-A., Schlötzer-Schrehardt, U., Schwarz, T.J.,... Lie, D.C. (2018). FoxO Function Is Essential for Maintenance of Autophagic Flux and Neuronal Morphogenesis in Adult Neurogenesis. Neuron, 99(6), 1188-1203.e6. https://dx.doi.org/10.1016/j.neuron.2018.08.017
Pachera, E., Assassi, S., Assassi, S., Salazar, G., Salazar, G., Frank-Bertoncelj, M.,... Distler, O. (2018). LONG NONCODING RNA H19X IS A MASTER REGULATOR OF EXTRACELLULAR MATRIX PRODUCTION IN SYSTEMIC SCLEROSIS. (pp. A10-A11).
Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C.-S., Thompson, A.M.,... Slamon, D. (2018). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, 19(1), 115-126. https://dx.doi.org/10.1016/S1470-2045(17)30716-7
Sahebi, F., Garderet, L., Kanate, A.S., Eikema, D.J., Knelange, N.S., Alvelo, O.F.,... Hari, P. (2018). Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biology of Blood and Marrow Transplantation. https://dx.doi.org/10.1016/j.bbmt.2018.09.018
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Kelemen, L.E., Earp, M., Fridley, B.L., Chenevix-Trench, G., Fasching, P.A., Beckmann, M.,... Berchuck, A. (2018). rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 19(9). https://dx.doi.org/10.3390/ijms19092473
Mathew, N.R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M.,... Zeiser, R. (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine. https://dx.doi.org/10.1038/nm.4484
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Herbst, F.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).

Last updated on 2016-21-04 at 08:24